Tecentriq will apply primary therapy benefits for liver and non-small cell lung cancer from May According to related industries, Roche Tecentriq will be applied to liver cancer and non-small cell lung cancer indicators from May as Merck and Pfizer Bavencio (Avelumab) passed the Cancer Drugs Benefit Appraisal Committee.

The benefit standards were set as the first solo maintenance therapy in adult patients with local progressive or metastatic urinary tract epithelial cell cancer that did not progress in platinum-based chemotherapy treatment. If benefit adequacy is recognized by the HIRA's Drug Benefit Evaluation Committee and drug price negotiations are concluded with the NHIS, it will be eligible for ins